{
  "name" : "twin.sci-hub.se_6503_5eb3c461de50112d01251326d41aaf37_han2016.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Gold-Nanoclustered Hyaluronan Nano- Assemblies for Photothermally Maneuvered Photodynamic Tumor Ablation",
    "authors" : [ "Hwa Seung Han", "Ki Young Choi", "Hansang Lee", "Minchang Lee", "Jae Yoon An", "Sol Shin", "Seunglee Kwon", "Doo Sung Lee", "Jae Hyung Park" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "KEYWORDS: hybrid nanomaterials, gold, hyaluronan, photothermal therapy, photodynamic therapy\nOrganic/inorganic hybrid nanomaterials have beenintensively investigated in the biomedical researchfield because they benefit not only from unique attributes of inorganic compartments like physical and chemical stability, bioinertness, and interesting optical properties1,2 but also from those of organic compartments such as biodegradability, plasticity, and flexibility of molecular design.3,4 Among the diverse hybrid nanomaterials, gold-based hybrid nanomaterials have shown great promise as a nanomedicine platform, because gold nanomaterials are considered nontoxic and biocompatible; they also have exciting optical properties such as a surface plasmon resonance (SPR) effect. To synthesize gold-based hybrid nanomaterials, gold nanomaterials such as gold nanoparticles, nanorods, or nanostars with diameters in the range of 50−200 nm have been widely used as core materials, and their surfaces have been modified with functional molecules like targeting moieties, for example, peptides,\nantibodies, or therapeutic/imaging agent to provide the gold nanomaterial with functionalities like disease-specific targetability or therapeutic activity.5−7\nRecent studies demonstrated an advanced approach to the preparation of gold-based hybrid nanomaterials, where relatively small gold nanoparticles (530 nm) and amphiphilic polymers were employed as building blocks to prepare micelle/ vesicle-type supramolecular self-assemblies.8−11 These studies employed gold nanoparticles as a scaffold or a basic building block for constructing supramolecular structures of gold nanoparticles, wherein the organic compartments generally serve as a connecting material, enabling gold nanoparticle selfassembly. Since spherical gold nanoparticles generally have an\nReceived: July 30, 2016 Accepted: October 24, 2016 Published: November 16, 2016\n© 2016 American Chemical Society 10858 DOI: 10.1021/acsnano.6b05113 ACS Nano 2016, 10, 10858−10868\nDOI: 10.1021/acsnano.6b05113 ACS Nano 2016, 10, 10858−10868\n10859\nSPR peak in the range of 500−550 nm, their in vivo application to photothermal therapy is limited due to the strong absorption by tissue, particularly hemoglobin, in the visible region.12\nHowever, with gold nanoparticles agglomerating into supramolecular assemblies, the SPR peak can red-shift to the nearinfrared (NIR) region; hemoglobin and water have their lowest absorption coefficient in the NIR region, which can facilitate photothermal therapy (PTT) in vivo. Recently, a variety of gold-based self-assemblies have been proposed as therapeutic platforms for drug delivery,9,13 PTT,8,9 and PDT/PTT dual therapy.8,14−16\nHerein, we report a biostable, photoactivatable hybrid nanomaterial based on a gold-nanoclustered hyaluronan nanoassembly (GNc-HyNA) to achieve complete tumor eradication empowered by sequential therapeutics of plasmonic PTT and photothermally boosted PDT. For the preparation of the hybrid nanomaterials in this study, we employed the polymeric nanoassembly of amphiphilic hyaluronan-polycaprolactone (Hy-PCL) conjugates as a polymeric reducing agent instead of using small molecule reducing agents such as sodium citrate or sodium borohydride. Unlike other supramolecular gold constructs based on metallic gold nanoparticle building blocks, this system uses nanoassembly as a polymeric nanoscaffold, which the gold nanoclusters can grow on and hydrophobic verteporfin (Vp), an FDA approved PDT agent,17,18 can abide in (Figure 1A). To grow gold nanoclusters on the polymeric self-assemblies, we did not exploit any surfactant such as cetyltrimethylammonium bromide. Since the nanoassembly is comprised of the hydrophilic hyaluronan (Hy) corona and hydrophobic PCL core, hydrophobic Vp molecules were able to be encapsulated in the hydrophobic PCL core. The Hy corona of the polymeric scaffold can also act as an active targeting ligand to facilitate CD44 mediated tumortargeting and cell permeation because the Hy receptor CD44 is known to be overexpressed on various tumor cells.19,20\nGiven the tertiary amine moieties introduced onto the Hy outer layer of the nanoassembly, gold nanoclusters can be selectively installed on the surface of the nanoassembly forming a gold shell. The gold shell acts as a diffusion barrier to impede premature release of Vp molecules from Vp-encapsulated GNcHyNA (Vp-GNc-HyNA) in the bloodstream, and it also serves as an optical barrier to protect the photoreactive Vp from external light, hindering singlet oxygen generation. It should be noted that hampering untimely release of Vp and singlet oxygen generation under physiological conditions reduces potential toxicity of the PDT agent to superficial tissues such as the skin or eyes upon exposure to sunlight after administration. PTT laser irradiation following GNc-HyNA treatment can induce significant increases in local temperature by a photothermal effect; the soaring heat can lead to dissociation of the Vp-GNc-HyNA, which markedly accelerates Vp release from Vp-GNc-HyNA and thus promptly activates the photodynamic effect upon PDT laser radiation. The photothermally boosted Vp release is even faster in cancer cells because Hy molecules can be degraded in the cells by hyaluronidases (Figure 2A); Hy enzymes known to be overexpressed in many types of cancer cells.21,22 In this report, we demonstrated (i) selective deposition of gold nanoclusters on the outer shell of a drug-loaded hyaluronan nanoassembly (HyNA) and (ii) the application of gold-nanoclustered polymeric nanoassemblies for photothermally activated photodynamic therapy."
    }, {
      "heading" : "RESULTS AND DISCUSSION",
      "text" : "For preparation of the HyNA, we synthesized an amphiphilic block copolymer by conjugating azide-functionalized PCL to αalkyne Hy conjugated with dimethylaminopropylamine (DAA)using facile click chemistry. In detail, an alkyne group was introduced to Hy by reductive amination with propargylamine in the presence of the reducing agent sodium cyanoborohydride (Supporting Information Figure S1). The 1H NMR spectrum confirmed the presence of both Hy and PCL, which indicates successful formation of block copolymers (Supporting Information Figure S2). DAA, which was chosen as a reducing moiety for formation of gold, was conjugated to the backbone of Hy through amide-bond formation. The successful synthesis of DAA-conjugated Hy-b-PCL was confirmed based on characteristic peaks of Hy (2.0 ppm), PCL (1.0 ppm), and DAA (2.2 ppm). The degree of substitution, defined as the number of DAA derivatives per 100 Hy repeating units, was found to be 31%. Owing to its amphiphilicity, the DAAmodified Hy-PCL conjugate could readily form micellar selfassemblies under aqueous conditions. Hy-PCL conjugates were self-assembled above the critical micelle concentration (CMC) of 72 μg/mL, which is significantly lower than that of low molecular weight detergent (Supporting Information Figure S3).23\nAfter preparing HyNA, we deposited gold nanoclusters on the HyNA surface by reducing gold-seed (Au-seed) using the polymeric reducing agent DAA-HyNA. To prepare GNcHyNA, we added HAuCl4 to HyNAs, on which gold ions nucleated and grew to form gold nanoclusters on the surface of the HyNAs; the gold nanoclusters were stabilized with the tertiary amine chains of the DAA groups.24−26 Successful anchoring of gold nanoclusters was confirmed by UV−vis spectroscopy as well as by energy dispersive X-ray photoelectron spectroscopy, which showed a pronounced peak for gold (Figure 1C,D and Supporting Information Figure S4B). The formation of gold nanoclusters on HyNAs enabled us to control the physicochemical properties of GNc-HyNAs. TEM images showed that both HyNAs and GNc-HyNAs were spherically shaped, but GNc-HyNA seemed much denser and to have uneven edges and a more compact shape compared to uncoated HyNAs (Figure 1B). The hydrodynamic diameters of HyNA and GNc-HyNA were found to be 204.0 ± 5.4 and 150.2 ± 3.1 nm, respectively (Supporting Information Table S1). The decrease in a diameter after installation of gold nanoclusters on HyNAs could be attributed to physical crosslinking with the gold nanoclusters, thereby forming a compact nanostructure. In addition to the physicochemical characteristics, the optical\nproperties of GNc-HyNA were also tailored with various amounts of HAuCl4 added to DAA-decorated HyNA. When 0.5 μM or a lower amount of Au-seed was added to the HyNA, a plasmon resonance peak around 550 nm was observed. However, when more than 0.9 μM of Au-seed was added, a new broad peak centered at 780 nm with ranges between 650 and 900 nm appeared due to the aggregation of Au nanoparticles.9,27,28 Thus, the photothermal effect of GNcHyNA was investigated. GNc-HyNA solutions were exposed to PTT laser at a power density of 1.5 W/cm2, which is known as a moderate power in PTT applications.9,29,30 GNc-HyNA added with 0.2 μM or 0.5 μM Au-seed showed a poor photothermal effect, and the temperature of the solutions slightly increased up to 39.1 or 33.9 °C, respectively, because\nDOI: 10.1021/acsnano.6b05113 ACS Nano 2016, 10, 10858−10868\n10860\ntheir SPR peaks were found in the range of 450 to 600 nm. Significant absorbance was not detected in the NIR region. By contrast, the temperature of the GNc-HyNA 0.9 μM solution soared to 74.1 °C given its strong SPR peak in the NIR region (Figure 1F−H). As the concentration of GNc-HyNA increased from 0.1 to 1 mg/mL, the solution temperature rose from 44 to 74 °C after PTT laser irradiation for 10 min, whereas temperature change for pure water exposed to PTT laser or Vp-GNc-HyNA solutions under PDT laser irradiation was negligible. The broad and red-shifted SPR spectra and the remarkable temperature increases indicated that GNc-HyNA with 0.9 μM of Au-seed would be suitable for NIR-based photothermal applications of GNc-HyNAs. In this study, we aimed to prepare a potent nanomedicine\nplatform that can be employed as a robust drug delivery carrier as well as a photothermally activatable PDT agent. To develop the nanomedicine platform, GNc-HyNA was exploited as a drug delivery carrier because the PCL-based hydrophobic inner core of HyNA can act as a drug reservoir. The PDT agent, Vp, was encapsulated in the PCL core, and gold was sequentially deposited on the surface of Vp-HyNA (Figure 2A). When 10 wt % of Vp was added, 90% and 87% of the added Vp was encapsulated into Vp-HyNA and Vp-GNc-HyNA, respectively (Supporting Information Table S2). To investigate the structural stability of Vp-GNc-HyNA, we monitored the changes in scattering intensities of the Vp-GNc-HyNA and\nVp-HyNA under serum-mimicking conditions (50% FBScontaining PBS) (Figure 2B). The Vp-GNc-HyNA maintained 63% of the initial intensity up to 9 h. However, the scattering intensity of Vp-HyNA steeply decreased by 26% of the initial intensity. These results suggest the Vp-GNc-HyNA can effectively maintain their structural integrity in a physiological environment and, thus, can securely protect drug molecules, which is one of the most important requisites for drug delivery carriers to efficiently deliver drugs to their target sites under physiological conditions. To investigate the photophysical and photochemical proper-\nties of Vp-GNc-HyNA, the fluorescence intensity of Vp-GNcHyNA was observed using a fluorescence spectrophotometer. Notably, when Vp was loaded in GNc-HyNA, its intrinsic fluorescence signals were highly quenched due to the strong surface plasmonic effect of the gold nanoclusters (Figure 2C).31,32 The pronounced quenching effect of Vp-GNc-HyNA was not confined to the fluorescence signals, but singlet oxygen generation was also conspicuously diminished in the GNcHyNA. To explore the ability of Vp-GNc-HyNA to generate singlet oxygen via the photodynamic effect, the nanoassemblies in an aqueous solution were irradiated with a 690 nm PDT laser, and singlet oxygen generation was monitored using pnitrosodimethylaniline (RNO) as a singlet oxygen sensor.33\nThe RNO concentration was recorded as a function of time under various conditions (Figure 2 E). Singlet oxygen\nDOI: 10.1021/acsnano.6b05113 ACS Nano 2016, 10, 10858−10868\n10861\ngeneration from Vp was impeded by a self-quenching effect when Vp was tightly aggregated in the micelle core as previously reported.34,35 In addition, gold nanoclusters on the GNc-HyNA hindered singlet oxygen generation of Vp due to energy transfer from the excited Vp to gold nanoclusters (Figure 2E).16 When Vp molecules were encapsulated by GNcHyNA, PDT laser radiation could not effectively generate singlet oxygen. This interesting PDT quenching phenomenon of Vp-GNc-HyNA not only indicates secure Vp loading in the nanoassemblies but also implies a possibility of minimizing nonspecific toxicity of PDT to patients who received PDT treatment upon exposure to sunlight. For Vp-GNc-HyNA to be an effective nanomedicine\nplatform, it must not generate toxic reactive oxygen species in the bloodstream or normal organs; however, it needs to effectively produce singlet oxygen at disease sites like tumor\ncells. Therefore, we demonstrated a further therapeutic application of Vp-GNc-HyNA that enables activatable, on-site photodynamic therapeutics. First, Vp-release profiles were monitored with Vp-GNc-HyNA incubated in PBS at 37 °C. The release rate of Vp from Vp-GNc-HyNA was slowed under physiological conditions (Figure 2D); only 30.8% of Vp was released in PBS within 48 h. However, the Vp release from VpGNc-HyNA under PTT laser irradiation dramatically accelerated. More than 73% of encapsulated Vp was released under exposure to the PTT laser at 48 h. Importantly, sequential radiation of PTT/PDT laser onto Vp-GNc-HyNA greatly boosted singlet oxygen generation as compared with that under single PDT laser treatment. This suggests that the gold shell of the Vp-GNc-HyNA significantly quenched the fluorescence signals of and suppressed singlet oxygen generation from Vp. Under sequential exposure to PTT/PDT laser, however, there\nDOI: 10.1021/acsnano.6b05113 ACS Nano 2016, 10, 10858−10868\n10862\nwas rapid Vp release followed by a remarkable recovery of both fluorescence signals and singlet oxygen generation, which consequentially augmented the PDT efficacy. One of the biggest advantages of the Vp-GNc-HyNA system is using a tumor cell-targeted nanocarrier based on Hy as a nanoscaffold. Since Hy can actively target the Hy-receptor, CD44, which is overexpressed on various types of tumor cells, HyNA could also readily target tumors by an active targeting mechanism.19,36−38 To test tumor targetability of the nanoassemblies in vitro, we examined cellular uptake of GNc-HyNA under confocal microscopy. GNc-HyNA labeled with the NIR fluorescence dye Cy5.5 was incubated with CD44-positive MDA-MB-231 breast cancer cells or CD44-less-positive NIH3T3 cells. Strong fluorescence signals from GNc-HyNA were observed in the cytosol of MDA-MB-231 cells, but only faint signals were detected in the NIH-3T3 cells (Supporting Information Figure S6). When we pretreated MDA-MB-231 cells with an excess amount of free hyaluronan molecules to block CD44 receptors, cellular uptake of GNc-HyNA was also significantly inhibited (Figure 3A). From these results, we confirmed that the uptake of GNc-HyNA into tumor cells was mainly attributable to the active interaction between hyaluronan and CD44 receptors on the cells. Although gold nanoclusters were installed on the surface of the nanoassemblies, Hy polymeric chains were still exposed on the surface of GNc-HyNA. The negative surface charge and CD44mediated endocytosis of GNc-HyNA substantiated that (Figure 3A, Supporting Information Table S1 and Figure S6). In addition, we also visualized intracellular Vp or gold nanoclusters delivered by Vp-GNc-HyNA. After Vp-GNcHyNA was incubated with MDA-MB-231 cells, noticeable fluorescence signals from Vp and dark-field signals from gold nanoclusters were observed in the cytosol of the cells (Figure 3B). Strong fluorescence signals from Vp in the cells indicate the release of Vp molecules from GNc-HyNA. Intracellular Vp release can mainly be ascribed to enzymatic degradation of the Hy backbone by the intracellular enzyme hyaluronidase, known to be overexpressed in various cancer cell lines.39,40 It is also attributed to the dissociation of the gold shell from Vp-GNcHyNA given the strong Au−S interaction (∼40 kcal/mol) between gold nanoclusters and intracellular glutathione (GSH) molecules, which can replace the Au−N interaction (∼8 kcal/ mol).41,42 To scrutinize the intracellular drug release mechanism, we monitored drug release profiles in the presence of two intracellular enzymes, GSH and hyaluronidase (Hyal). Incubating Vp-GNc-HyNA with GSH and Hyal significantly accelerated Vp release (Figure 3C). In PBS, <20% of Vp was released from Vp-GNc-HyNA within 6 h, while for GSH and Hyal, over 50% of the Vp was released. Moreover, more than 80% of Vp was released when Vp-GNc-HyNA was incubated with GSH and Hyal and sequentially exposed to PTT laser. Likewise, in the presence of GSH and Hyal with sequential laser treatment of PTT and PDT, the rate of singlet oxygen generation was significantly higher than other groups. The amount of singlet oxygen generation from Vp-GNc-HyNA (Hyal + GSH + PTT + PDT) was 2.6-fold and 1.7-fold higher than that of either single laser or dual laser treatment (Figure 3D). The results demonstrate that Vp-GNc-HyNA was slowly disintegrated by intracellular GSH and Hyal, and it was completely dissociated upon PTT laser radiation, which facilitated an extensive discharge of Vp and dramatically boosted singlet oxygen generation from Vp-GNc-HyNA upon PDT laser irradiation. We further studied the cytotoxicity of\nVp-GNc-HyNA on MDA-MB-231 cells (Figure 3E). As expected, the GNc-HyNA or Vp-GNc-HyNA did not induce noticeable cytotoxicity without laser irradiation (Supporting Information Figure S5A,B). However, substantial cytotoxicity was induced in cells exposed to PDT, PTT, or sequential PDT/ PTT laser treatment. Interestingly, Vp-GNc-HyNA treated sequentially with PTT laser and PDT laser irradiation led to even stronger cytotoxicity than Vp-HyNA under PDT laser, Vp-GNc-HyNA under PTT, or PDT laser alone (Figure 3E). Treatment with Vp-GNc-HyNA and sequential PTT/PDT laser radiation resulted in the highest anticancer efficacy among the treatment groups. We evaluated the in vivo behavior of Vp-GNc-HyNA. For the in vivo study, we established subcutaneous tumor models and orthotopic breast tumor models prepared by subcutaneously or orthotopically injecting MDA-MB-231 human breast cancer cells into the mammary gland of Balb/c nude mice; these models are considered more clinically relevant and better predictive models for drug evaluation than subcutaneous models. First, we monitored time-dependent biodistribution of the nanoparticles using in vivo NIR fluorescence microscopy after intravenous administration of GNc-HyNA labeled with Cy5.5 into both subcutaneous and orthotopic breast tumor models (Figure 4A,D). Fluorescence signals from the GNcHyNA were found all over the body 1 h postinjection, and the signals gradually diminished as time passed; thus, only feeble fluorescence signals were found in the body 24 h postinjection. Interestingly, stronger fluorescence signals were detected at tumor sites 1 h after injection than seen in the whole body. The fluorescence signals gradually increased and reached the highest level at 9 h (Figure 4B,E). It is important to note that the strong fluorescence intensities in the tumor remained steady at 24 h, whereas those from the whole body rapidly decreased. These results imply that GNc-HyNA can circulate in the bloodstream and rapidly target tumors. While GNc-HyNA is readily excreted from the body, it can stay in tumor tissues for a prolonged period of time, possibly due to impaired lymphatic drainage in tumor tissues.43,44\nTo evaluate the relative organ and tumor distribution of GNc-HyNA, the major organs of subcutaneous tumor xenograft mice and orthotopic breast tumor mice were harvested 2 days after injection, and the fluorescence signals of the organs under an in vivo imaging system were examined (Figure 4C,F). Ex vivo organ images showed that GNc-HyNA could accumulate at high levels in tumor, liver, and kidney tissues, but the tumor accumulation was greater than that of the other organs. The gold accumulated in the major organs was quantified by ICPMS at different time points (Figure 4H). We found that GNcHyNA accumulated prominently in tumor, liver, and spleen tissues on day 1. More than 25.1% of injected gold was found in tumor tissues, and 36.1% and 16.9% were detected in liver and spleen tissues, respectively. Compared to the gold contents on day 1, accumulated gold contents rapidly decreased in the organs as the day progressed; over 69.8% and 50.2% of the gold content accumulated in liver and spleen tissues were cleared by day 7, and over 86.1% and 92.9% were cleared by day 14. On the other hand, over 56.1% of gold accumulated in tumor tissues remained by day 7, and 20.4% remained on day 14, which demonstrated prolonged retention effect of nanostructures in tumor tissues. We further confirmed tissue distribution of the PDT agent Vp delivered with GNc-HyNA by detecting fluorescence signals of Vp at both tumors and organs (Supporting Information Figure S7).\nDOI: 10.1021/acsnano.6b05113 ACS Nano 2016, 10, 10858−10868\n10863\nIn accordance with the biodistribution of GNc-HyNA, the strongest Vp signals were detected in tumors compared to the other organs; considerable Vp accumulation was also detected in the liver and kidney. Notably, the nonspecific accumulation of GNc-HyNA was not considered a major issue in this study because the Vp-GNc-HyNA was found to be nontoxic without the photoactivation steps by PTT and/or PDT laser radiation. Therefore, Vp-GNc-HyNA could provide a potent therapeutic regimen with excellent tumor targetability combined with PTT/PDT laser irradiation. After we substantiated favorable tumor-targetability of GNc-HyNA by in vivo fluorescence imaging and ICP-MS, we also examined the photothermal properties of GNc-HyNA in vivo. A thermal camera was used to record the temperature change. The local tumor temperature of PBS control group upon PTT laser irradiation at a laser power density of 1.5 W/cm2 for 5 min did not significantly change, implying that the low-power NIR laser is harmless to organs (Figure 4G,I). However, the local tumor temperature of mice treated with Vp-GNc-HyNA and PTT laser rapidly increased to\n60 °C, which exceeds the damage threshold needed for tumor treatment.45,46\nTo verify the photothermal therapeutic activity using VpGNc-HyNA, we prepared orthotopic breast tumor models because they are considered more clinically relevant models for drug evaluation than subcutaneous models. The tumors were exposed to PTT and/or PDT laser 9 h after Vp-GNc-HyNA, Vp, or saline was injected into the tail veins of the orthotopic tumor animals, and tumor volume and survival rate were recorded (Figure 5A). In the saline (without laser radiation and sample injection) and laser groups (PTT/PDT laser without injecting samples), tumors grew rapidly, resulting in an 8-fold increase in volume within 20 days. Tumor volumes of the Vp group (with PDT laser) also increased 6 fold in 20 days, indicating that a low dosage of free Vp was not effective enough to suppress tumor growth. As for Vp-GNc-HyNA (PDT), the growth rate of tumors was remarkably lessened, but the tumors of the group still grew after treatment. The Vp-GNc-HyNA with PTT laser-treated group successfully suppressed tumor\nDOI: 10.1021/acsnano.6b05113 ACS Nano 2016, 10, 10858−10868\n10864\ngrowth, but PTT laser treatment was also not enough to completely remove the tumors, and the scar was not totally healed after 50 days. On the other hand, tumors in the VpGNc-HyNA with PTT/PDT sequential laser treatment group were completely ablated without any scar remaining; the skin was fully regenerated after the treatment (Figure 5C). Surprisingly, all of the mice of the Vp-GNc-HyNA with PTT/PDT laser treat group survived after 50 days without a single death or tumor recurrence, whereas mice of the other groups showed relatively short life spans. Mice from the saline control group, the laser (PDT + PTT) only group, and the free VP with PDT laser group did not survive over 33, 35, and 39 days, respectively, after the treatments started. Even for the VpGNc-HyNA with PDT laser or with PTT laser, only 40% and 80%, respectively, of mice survived at day 50 (Figure 5B)."
    }, {
      "heading" : "CONCLUSIONS",
      "text" : "In this report, we demonstrated a biostable, photo- and enzyme-activatable hybrid nanomaterial based on a goldnanoclustered HyNA that can be employed as a potent PTT agent and as a photothermally activatable smart PDT nanoformulation. Using Vp-GNc-HyNA treatment in an orthotopic breast tumor model, we demonstrated that tumors were completely ablated with a 100% survival rate over the 50 days post-treatment. The fascinating therapeutic nanomedicine applications based on Vp-GNc-HyNA may open up possibilities for the eradication of tumors."
    }, {
      "heading" : "MATERIALS AND METHODS",
      "text" : "Materials. Sodium hyaluronate (MW = 12000 Da) was purchased from Lifecore Biomedical (Chaska, MN, U.S.A.). 3-(Dimethylamino)1-propylamine (DAA), propargylamine (98%), sodium cyanoborohydride (reagent grade, 95%), triethylamine (≥99%), copper(II) sulfate pentahydrate (CuSO4·5H2O), ε-caprolactone, tin(II) 2-ethylhexanoate, sodium azide (NaN3), 1-hyroxybenzotriazole (HOBt), ptoluenesulfonyl chloride (p-TsCl), 1-ethyl-3(3-(dimethylamino)propyl) carbodiimide· hydrochloride (EDC·HCl), L-glutathione reduced (GSH), gold(III) chloride trihydrate, and cell counting kit-8 (CCK-8) were obtained from Sigma-Aldrich Co. (St. Louis, MO, U.S.A.). Hyaluronidase was purchased from Tokyo Chemical Industry Co. (Tokyo, Japan). Verteporfin (Vp) was obtained from MedKoo Biosciences, Inc. (Chapel Hill, U.S.A.). The NIR dye, Cy5.5, was purchased from Bioacts (Incheon, Korea). Water, used for synthesis and characterization in this experiment, was purified using an AquaMax-Ultra water purification system (Younglin Co., Anyang, Korea). MDA-MB-231 cells were obtained from the Korea Cell Line Bank (KCLB, Seoul, Korea). All other chemicals were analytical grade and used as received. Synthesis of Vp-Loaded Hyaluronan Nanoassembly (VpHyNA). Hyaluronan nanoassemblies (HyNA) were prepared via click chemistry using alkyne-terminated hyaluronan (α-alkyne Hy) and azide-terminated polycaprolactam (PCL-N3, MW = 5774 g/mol), as previously reported.47 Tertiary amine containing DAA was conjugated to the backbone of α-alkyne Hy in the presence of EDC and HOBt. Briefly, α-alkyne Hy (200 mg, 0.527 mmol) was dissolved in 50 mL of distilled water with EDC·HCl (163.94 mg, 1.056 mmol), HOBt (161.70 mg, 1.056 mmol), and DAA (21.56 mg, 0.264 mmol). The pH of the solution was adjusted to 6.8, and the solutions were stirred at room temperature for 24 h. The resulting mixture was purified by dialysis (MW cutoff = 1000 Da) against distilled water for 2 days, followed by lyophilization to obtain DAA-conjugated α-alkyne HA. DAA-conjugated Hy-b-PCL copolymer was synthesized by a Huisgen’s 1,3-dipolar cycloaddition reaction. In brief, DAA-conjugated α-alkyne Hy (200 mg, 0.015 mmol) and PCL-N3 (64 mg, 0.01 mmol) were dissolved in deionized water and degassed DMF, respectively. The solutions were mixed with CuSO4·5H2O (10.60 mg, 0.042 mmol) and\nsodium ascorbate (8.41 mg, 0.042 mmol). Thereafter, the mixture was stirred at 45 °C for 2 days and dialyzed against water (MW cutoff = 3.5 kDa) to remove excess Hy, followed by lyophilization to obtain HyNA. The CMC of HyNA was evaluated using fluorescence spectroscopy in the presence of pyrene molecules as previously reported.19 Pyrene fluorescence spectra was obtained by using a fluorescence spectrophotometer (FluoroMatye FS-2, SINCO Co., Ltd., Seoul, Korea). Vp was loaded into HyNA using a simple dialysis method. In brief, a predetermined amount of Vp (11 mg) in 1 mL of DMSO/distilled water (1:1, v/v) was slowly added to HyNA (100 mg) dissolved in 10 mL of the same cosolvent. Afterward, the solution was sonicated for 3 min using a probe type sonicator (VCX-750, Sonics & Materials, CT, U.S.A.) and dialyzed for 12 h against distilled water using a dialysis membrane (MW cutoff = 6−8 kDa). After filtering through a 0.8 μm syringe filter to remove unloaded Vp, the product was lyophilized to obtain a dark powder (Vp-HyNA). For in vitro cellular uptake and in vivo biodistribution studies, Cy5.5 monohydrazide was chemically conjugated to the carboxylic acid groups on the hyaluronan backbone via the amide formation. In brief, HyNA (30 mg) was dispersed in the phosphate buffer (4 mg/mL, 10 mM, pH 6.8) and was stirred for 12 h in the presence of EDC (1.2 mg) and HOBt (0.9 mg). The solution was purified by dialysis (MW = 12−14000 Da) against distilled water for 2 days, followed by lyophilization to obtain Cy5.5-HyNA.\nFabrication and Characterization of Gold-Nanoclustered Vp-HyNA (Vp-GNc-HyNA). To optimize gold nanoclusters formation onto HyNA, various feed molar ratios of HAuCl4·3H2O were added to the Vp-HyNA solution. In brief, Vp-HyNA (2 mg/mL) was dispersed in deionized water and mixed with the gold stock solution, in which the feed molar ratio of HAuCl4 to the tertiary amine in HyNA was adjusted in the range of 0.05−0.5. The mixture was stirred under dark conditions at room temperature for 24 h and centrifuged at 15,000 g for 30 min to remove unreacted gold. Finally, the product was lyophilized to obtain gold-nanoclustered nanoparticles (Vp-GNcHyNA). Samples of GNc-HyNA were dissolved in DMSO-d6/D2O, and the chemical were characterized using 1H NMR (Varian Unity Inova 500NB, Sparta, NJ, U.S.A.) operating at 500 MHz. The sizes and surface zeta potential of the nanoparticles were determined at 25 °C using a Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, U.K.). Nanoparticle morphology was observed using a HR-TEM (JEOL-2100F, Tokyo, Japan) operated at an accelerating voltage of 200 kV. For TEM images, samples were dispersed in deionized water (1 mg/mL) and dropped on a 200-mesh copper grid. In particular, HyNA and GNc-HyNA were treated with 0.5% uranyl acetate for negative staining. Energy dispersive X-ray photoelectron spectroscopy measurements were performed using a JEOL JEM-2100F equipped with an EDX Genesis Series γ-TEM at 200 kV. The quantity of gold nanoclusters in nanoparticle was measured using an inductively coupled plasma mass spectrometry (ICP-MS Agilent 7500, Agilent Technologies Inc., CA, U.S.A.). To determine the drug loading content and loading efficiency, Vp-HyNA and Vp-GNc-HyNA were dissolved in a DMSO/DIW solution 1:1 (v/v), and the Vp concentration was estimated by measuring fluorescence at 700 nm using a fluorescence spectrophotometer.\nStability of Vp-GNc-HyNA. Size stability of Vp-GNc-HyNA was investigated in PBS containing 50% fetal bovine serum (FBS) using a DLS.48 In brief, nanoparticles (10 mg) were dispersed in 10 mL of PBS containing 50% FBS at 37 °C and changes in scattering intensities of the solutions were monitored as a function of time using a DLS. The solution was stirred using an orbital shaker (KE011−200, Komabiotech, Seoul, Korea). At predetermined time points, the ratio of scattered light intensity was monitored. For comparison, the stability of Vp-HyNA was estimated under the same conditions.\nIn Vitro Vp Release Test and Singlet Oxygen Generation of Vp-GNc-HyNA. The Vp release behavior from Vp-GNc-HyNA was evaluated using a dialysis method. Samples in a PBS solution (1 mL, 1 g/L, pH 7.4) containing GSH or Hyal were placed in a dialysis membrane bag (MW cutoff = 3500) and exposed with or without a 808 nm PTT laser (Changchun New Industries Optoelectronics Technology Co., Ltd., Changchun, China). The medium was shaken at a speed of 100 rpm at 37 °C. At predetermined time intervals, the\nDOI: 10.1021/acsnano.6b05113 ACS Nano 2016, 10, 10858−10868\n10865\nrelease medium was refreshed by transferring the dialysis tube to fresh release medium. The amount of Vp released was quantified by measuring Vp absorbance at 690 nm, what was based on the standard concentration curve of free Vp in DMSO. To quantitatively evaluate generation of singlet oxygen from Vp, Vp-GNc-HyNA (100 μg/mL of Vp) in 200 μL of 1% DMSO solution in distilled water was added to 3.8 mL of distilled water containing 5.58 mg of L-histidine and 0.377 μg of RNO, and the resulting solution was exposed to a 690 nm laser (Shanghai Dream Laser Technology Co., Ltd., Shanghai, China) or PTT Laser The absorbance of RNO was measured at 405 nm using a UV−vis spectrometer as a function of time. In Vitro Photothermal Effect and in Vivo Photothermal Imaging of Vp-GNc-HyNA. To investigate the in vitro photothermal effect of Vp-GNc-HyNA, Vp-GNc-HyNA was dispersed in deionized water at concentrations of 1, 0.5, and 0.1 mg/mL. The solutions were irradiated at 808 nm via an optical fiber with 1.5 W/cm2, and the temperatures of the solutions were recorded over 10 min using a digital thermometer (TES-1300, TES, Taiwan). To measure in vivo photothermal imaging of Vp-GNc-HyNA, samples (200 μL, 1 mg/ mL) were intravenously injected into MDA-MB-231 tumor-bearing mice (female, 20−25g) and irradiated for 5 min with the PTT laser at a power density of 1.5 W. Real-time thermal imaging of MDA-MB-231 tumors was monitored by photothermal camera (T430sc, FLIR Systems, Inc., Wilsonville, U.S.A.). In Vitro Cellular Uptake and Phototoxicity of Vp-GNc-HyNA. MDA-MB-231 and NIH-3T3 cells were cultured in a RPMI medium (Gibco, Grand Island, NY, U.S.A.) containing 10% FBS and 1% penicillin-streptomycin at 37 °C in a humidified 5% CO2 atmosphere. To determine the cellular uptake and distribution of Cy5.5-labeled or Vp loaded HyNA, cells (1 × 105cells/well) were seeded onto gelatincoated coverslip in 6-well plates and treated with Cy5.5-labeld GNcHyNA (100 μg/mL), Vp, and Vp-GNc-HyNA (30 μg/mL) for 3h at 37 °C in a CO2 incubator. For competitive inhibition studies, cells were pre-exposed to 2 mL of serum-free medium containing Hy (5 mg/mL) for 1 h. The cells were then washed twice with DPBS and fixed with a 4% paraformaldehyde solution. After 4,6-diamidino-2phenylindole (DAPI) mounting, the cells were observed using confocal laser microscopy (Zeiss LSM 700, Carl Zeiss, Oberkochen, Germany). The uptake of gold nanoclusters in the nanoparticles was visualized using IX81-ZDC focus drift compensating microscopy (Olympus, Tokyo, Japan). To assay the phototoxicity of Vp-GNcHyNA in the cell culture system, cells were seeded at 1 × 104 cells/ well in 96-well plates and stabilized for 24 h. After incubation with various concentrations of sample (0.005−50 μM of Vp), all cells were illuminated with a PDT or PTT laser for a predetermined irradiation time. Following a 6 h postincubation period under dark conditions, the phototoxicity of samples was evaluated using CCK-8 (Sigma, St. Louis, MO). In Vivo Biodistribution of Vp-GNc-HyNA. All experiments with live animals were performed in compliance with relevant laws and institutional guidelines of Sungkyunkwan University, and institutional committees approved all experiments. To observe the in vivo biodistribution of Cy5.5-labeled GNc-HyNA and Vp-GNc-HyNA, orthotopic or xenograft MDA-MB-231 tumor-bearing mice were prepared by injecting a suspension of 1 × 107 MDA-MB-231 cells in saline (100 μL) into the dorsal subcutaneous tissue of nude mice (Orientbio Inc., Seongnam, Korea). When tumors grew to approximately 150−200 mm3 in volume, 200 μL of solution containing nanoparticles (1 mg/mL) was injected into the mice via the tail vein (n = 3 per each group). The time-dependent biodistribution and accumulation profiles of the nanoparticles were monitored with the eXplore Optix system (ART advanced Research Technologies, Inc., Montreal, Canada). To observe the organ distribution of nanoparticles, each group of mice was sacrificed 24 h postinjection. Then, major organs and tumors were excised and observed using the eXplore Optix system. All data were calculated using the region of interest function of the Analysis Workstation software (ART Advanced Research Technologies, Inc., Montreal, Canada), and values are presented as the means with standard deviations for groups of at least three animals.\nIn Vivo Antitumor Efficacy of Laser Treatment. To evaluate the photodynamic and photothermal effects of Vp-GNc-HyNA, MDAMB 231 tumor-bearing mice were prepared as follows. A suspension of 1 × 107 MDA-MB 231 cancer cells in physiological saline (100 μL) was subcutaneously injected into the dorsa of athymic nude mice. Mice were divided into six groups: (1) saline, (2) laser (PTT and PDT laser treatment), (3) Vp (at 5 mg/kg) with PDT laser, (4) Vp-GNc-HyNA with PDT laser, (5) Vp-GNc-HyNA with PTT laser, and (6) Vp-GNcHyNA with PTT laser and PDT laser. When the tumor volume reached 200 mm3, each treatment was introduced at day 0 via tail-vein injection. Subsequently, PTT treatment (5 min, 808 nm, 1.5 W/cm2), PDT treatment (20 min, 690 nm, 0.5 W/cm2), and a sequence of initial PTT and subsequent PDT treatment (PTT/PDT) were performed 9 h postinjection. Volumes were observed once per day for 20 days. Tumor volumes were calculated as [a × b2/2], where a was the largest and b the smallest diameter. The values are presented as the mean with standard deviation for groups of five animals.\nStatistical Analysis. The difference between experimental and control groups was analyzed using one-way ANOVA and considered statistically significant (marked with an asterisk (*) in figures) if p < 0.05."
    }, {
      "heading" : "ASSOCIATED CONTENT",
      "text" : "*S Supporting Information The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsnano.6b05113.\nSynthetic scheme, additional images, and graphs (PDF)\nAUTHOR INFORMATION Corresponding Author *E-mail: jhpark1@skku.edu."
    }, {
      "heading" : "Author Contributions",
      "text" : "§These authors contributed equally. J.H.P., D.S.L., H.S.H., and K.Y.C. designed and performed the experiments. M.L. and J.Y.A. contributed to the cell experiments. H.L., S.S., and S.K. contributed to the animal experiments. H.S.H. and K.Y.C. wrote the paper."
    }, {
      "heading" : "Notes",
      "text" : "The authors declare no competing financial interest."
    }, {
      "heading" : "ACKNOWLEDGMENTS",
      "text" : "This research was supported by the Basic Science Research Program (2015R1A6A3A04059033, 2015R1A2A2A05001390, and 20100027955) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Republic of Korea. The authors would like to thank Ms. Hwayoung Lee for her input on the illustrations."
    } ],
    "references" : [ {
      "title" : "Hybrid Nanoparticles for Detection and Treatment of Cancer",
      "author" : [ "M.J. Sailor", "J.-H. Park" ],
      "venue" : "Adv. Mater. 2012,",
      "citeRegEx" : "Sailor and Park,? \\Q2012\\E",
      "shortCiteRegEx" : "Sailor and Park",
      "year" : 2012
    }, {
      "title" : "A clearer vision for in vivo imaging",
      "author" : [ "R. Weissleder" ],
      "venue" : "Nat. Biotechnol",
      "citeRegEx" : "Weissleder,? \\Q2001\\E",
      "shortCiteRegEx" : "Weissleder",
      "year" : 2001
    }, {
      "title" : "Dual Imaging-Guided Photothermal/Photodynamic Therapy using Micelles",
      "author" : [ "H. Chen" ],
      "venue" : "Biomaterials 2014,",
      "citeRegEx" : "Chen,? \\Q2014\\E",
      "shortCiteRegEx" : "Chen",
      "year" : 2014
    }, {
      "title" : "Smart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer Therapy",
      "author" : [ "J.H. Park" ],
      "venue" : "ACS Nano 2011,",
      "citeRegEx" : "Park,? \\Q2011\\E",
      "shortCiteRegEx" : "Park",
      "year" : 2011
    } ],
    "referenceMentions" : [ ],
    "year" : 2016,
    "abstractText" : "Optically active nanomaterials have shown great promise as a nanomedicine platform for photothermal or photodynamic cancer therapies. Herein, we report a gold-nanoclustered hyaluronan nanoassembly (GNc-HyNA) for photothermally boosted photodynamic tumor ablation. Unlike other supramolecular gold constructs based on gold nanoparticle building blocks, this system utilizes the nanoassembly of amphiphilic hyaluronan conjugates as a drug carrier for a hydrophobic photodynamic therapy agent verteporfin, a polymeric reducing agent, and an organic nanoscaffold upon which gold can grow. Gold nanoclusters were selectively installed on the outer shell of the hyaluronan nanoassembly, forming a gold shell. Given the dual protection effect by the hyaluronan self-assembly as well as by the inorganic gold shell, verteporfin-encapsulated GNc-HyNA (Vp-GNc-HyNA) exhibited outstanding stability in the bloodstream. Interestingly, the fluorescence and photodynamic properties of Vp-GNcHyNA were considerably quenched due to the gold nanoclusters covering the surface of the nanoassemblies; however, photothermal activation by 808 nm laser irradiation induced a significant increase in temperature, which empowered the PDT effect of Vp-GNc-HyNA. Furthermore, fluorescence and photodynamic effects were recovered far more rapidly in cancer cells due to certain intracellular enzymes, particularly hyaluronidases and glutathione. Vp-GNc-HyNA exerted a great potential to treat tumors both in vitro and in vivo. Tumors were completely ablated with a 100% survival rate and complete skin regeneration over the 50 days following Vp-GNc-HyNA treatment in an orthotopic breast tumor model. Our results suggest that photothermally boosted photodynamic therapy using Vp-GNc-HyNA can offer a potent therapeutic means to eradicate tumors.",
    "creator" : "Arbortext Advanced Print Publisher 10.0.1465/W Unicode"
  }
}